UK Cell Reprogramming Market Size & Outlook, 2025-2030

The cell reprogramming market in UK is expected to reach a projected revenue of US$ 41.4 million by 2030. A compound annual growth rate of 11.4% is expected of UK cell reprogramming market from 2025 to 2030.
Revenue, 2024 (US$M)
$22.0
Forecast, 2030 (US$M)
$41.4
CAGR, 2025 - 2030
11.4%
Report Coverage
UK

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

UK cell reprogramming market, 2018-2030 (US$M)

UK cell reprogramming market, 2018-2030 (US$M)

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

UK cell reprogramming market highlights

  • The UK cell reprogramming market generated a revenue of USD 22.0 million in 2024 and is expected to reach USD 41.4 million by 2030.
  • The UK market is expected to grow at a CAGR of 11.1% from 2025 to 2030.
  • In terms of segment, episomal reprogramming was the largest revenue generating technology in 2024.
  • MRNA Reprogramming is the most lucrative technology segment registering the fastest growth during the forecast period.

Cell reprogramming market data book summary

Market revenue in 2024USD 22.0 million
Market revenue in 2030USD 41.4 million
Growth rate11.1% (CAGR from 2025 to 2030)
Largest segmentEpisomal reprogramming
Fastest growing segmentMRNA Reprogramming
Historical data2018 - 2023
Base year2024
Forecast period2025 - 2030
Quantitative unitsRevenue in USD million
Market segmentationSendai Virus-based Reprogramming, MRNA Reprogramming, Episomal Reprogramming
Key market players worldwideThermo Fisher Scientific Inc, Merck KGaA, Bio-Techne Corp, ReproCELL, Lonza Group Ltd, FUJIFILM Holdings Corp, Astellas Pharma Inc, Allele Biotech, Alstem, STEMCELL Technologies

Other key industry trends

  • In terms of revenue, UK accounted for 5.4% of the global cell reprogramming market in 2024.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In Europe, UK cell reprogramming market is projected to lead the regional market in terms of revenue in 2030.
  • UK is the fastest growing regional market in Europe and is projected to reach USD 41.4 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Cell Reprogramming Market Companies

Name Profile # Employees HQ Website
Alstem View profile 11-50 Richmond, Virginia, United States, North America https://www.alstembio.com/web/
Allele Biotech View profile 11-50 San Diego, California, United States, North America http://www.allelebiotech.com/
STEMCELL Technologies View profile 501-1000 Vancouver, British Columbia, Canada, North America https://www.stemcell.com
ReproCELL View profile 51-100 Yokohama, Kanagawa, Japan, Asia http://reprocell.com
Astellas Pharma Inc View profile 14484 2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, Japan, 103-8411 http://www.astellas.com
Bio-Techne Corp View profile 3050 614 McKinley Place N.E., Minneapolis, MN, United States, 55413 https://www.bio-techne.com
Thermo Fisher Scientific Inc View profile 122000 168 Third Avenue, Waltham, MA, United States, 02451 https://www.thermofisher.com
FUJIFILM Holdings Corp View profile 83784 7-3, Akasaka 9-chome, Minato-ku, Tokyo, Japan, 107-0052 http://www.fujifilmholdings.com
Lonza Group Ltd View profile 18000 Muenchensteinerstrasse 38, Basel, Switzerland, CH-4002 https://www.lonza.com
Merck KGaA View profile 62345 Frankfurter Strasse 250, Darmstadt, HE, Germany, 64293 https://www.emdgroup.com

UK cell reprogramming market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell reprogramming market will help companies and investors design strategic landscapes.


Episomal reprogramming was the largest segment with a revenue share of 33.18% in 2024. Horizon Databook has segmented the UK cell reprogramming market based on sendai virus-based reprogramming, mrna reprogramming, episomal reprogramming covering the revenue growth of each sub-segment from 2018 to 2030.


The cell reprogramming market in the UK is driven by the presence of numerous cell reprogramming companies, such as Mogrify Limited, bit.bio, and Algocells. These companies are undertaking various business initiatives to gain maximum market share, which is contributing to the growth of the cell reprogramming market in the country.

For instance, in May 2023, Mikonos, Inc., a biotechnology platform specializing in cell therapies through innovative chip technology, announced a new research collaboration with bit.bio. This partnership aims to assess and refine the nonviral delivery of bit.bio's patented safe harbor gene targeting methodology.

The approach involves inducible expressing transcription factor combinations, expediting the advancement of human cells for applications in research, reprogramming human iPSCs, drug discovery, and next-generation cell therapies.

Reasons to subscribe to UK cell reprogramming market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of UK cell reprogramming market databook

  • Our clientele includes a mix of cell reprogramming market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the UK cell reprogramming market , including forecasts for subscribers. This country databook contains high-level insights into UK cell reprogramming market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

UK cell reprogramming market size, by technology, 2018-2030 (US$M)

UK Cell Reprogramming Market Outlook Share, 2024 & 2030 (US$M)

UK cell reprogramming market size, by technology, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more
Chat with us
Research Assistance
Online